Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

Abstract

Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free survival. Data support the use of RopegIFN in both early PV therapy and second-line and beyond.

Keywords

• ph-negative chronic myeloproliferative neoplasm
• chronic myeloproliferative neoplasms
• neoplasia
• hematopoietic stem and progenitor cells
• hematopoiesis
• pharmacotherapeutics
• neoplasia
• oncogenes